Cat. No.: X24-06-ZQ444
Bcr-Abl inhibitor DCC-2036, Purity ≥98%
Synonym: 1020172-07-9; Bcr-Abl inhibitor; DCC2036
- MDL: MFCD19443646
- CAS Number: 1020172-07-9
- Compound CID: 25066467
Product Size
5 mg; 10 mg; 50 mg; 100 mg
Properties
Description
DCC-2036, soluble in DMSO and ethanol and insoluble in water, specifically inhibits the activity of the Bcr-Abl tyrosine kinase. It targets Abl1 (H396P), p-Abl1 (native), AuroraA, c-Kit, CDK2/CyclinD, FGR, FLT3, HCK, KDR, Lyn, and p-Abl1(T315I).
Molecular Formula
C30H28FN7O3
Targets
Abl1 (H396P): 1.4 nM; p-Abl1 (native): 2 nM; AuroraA: >5 μM; c-Kit: 481 nM; CDK2/CyclinD: >5 μM; FGR: 38 nM; FLT3: 2 nM; HCK: 40 nM; KDR: 4 nM; Lyn: 29 nM; p-Abl1 (T315I): 4 nM
Solubility
DMSO: 103 mg/mL (186.05 mM); Water: Insoluble; Ethanol: 15 mg/mL (27.09 mM)
Identity
Confirmed by NMR/HPLC/MS.
Applications
DCC-2036 offers a framework for researching alternative therapies to overcome resistance in chronic myeloid leukemia.
Related Products
Quick Links